<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2017.71004</article-id><article-id pub-id-type="publisher-id">ACM-19994</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20170100000_47547940.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  靶向DPP4与2型糖尿病相关药物分子的对接研究
  The Docking of Protein DPP4 and Drug Molecules for Type 2 Diabetes
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>恒臻</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>庄</surname><given-names>立晖</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>刘</surname><given-names>哲</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>晓艳</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>泰山医学院放射学院，山东 泰安</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>09</day><month>03</month><year>2017</year></pub-date><volume>07</volume><issue>01</issue><fpage>16</fpage><lpage>22</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    DPP-4抑制剂作为一种治疗2型糖尿病的新型药物正在崭露头角，本文利用分子对接技术研究DPP4蛋白与5种抑制剂之间的对接研究，以期对新的抑制剂的研究提供帮助。结果表明：阿格列汀抑制剂与DPP4对接过程中与GLU206，TYR662，ARG125处结合形成氢键，与GLU205处形成盐桥；沙格列汀与DPP4对接过程中在GLU205，GLU206、TYR662，ARG125部位形成氢键，并在骨架的GLU205处形成氢键；利拉利汀与DPP4对接过程中在GLU205，TYR662，ARG125部位形成氢键，在GLU206处形成盐桥，而在TUR547处形成了π-π作用；西他列汀与DPP4对接过程中在GLU205，TYR662部位形成氢键，在GLU206处形成盐桥，而在TYR666处形成了π-π作用；维格列汀与DPP4对接过程中在GLU205部位形成氢键，在GLU206处形成盐桥。
    DPP 4 inhibitors are emerging as new drugs for type 2 diabetes treatment. In this paper we use molecular docking technology between DPP4 protein and 5 kinds of inhibitors in order to help to understanding the study of new inhibitors. The results showed that the hydrogen bonds are formed between Alogliptin inhibitor and DPP4 at GLU206, TYR662, ARG125; salt bridge is formed at GLU205; there are also hydrogen bond in GLU205, GLU206, TYR662, ARG125 between saxagliptin and Dpp4. Also one hydrogen bonding is formed between the backbone with residue GLU205; Linagliptin formed hydrogen at GLU205, TYR662, ARG125, also formed salt bridge at GLU206 bridge and had Pi-Pi interaction at TUR547; Sitagliptin had hydrogen bond at GLU205 and TYR662, salt bridge at GLU206, and PI-PI interaction at TYR666 during docking process; Vilagliptin formed hydrogen bonds at GLU205D and salt bridge at GLU206. 
  
 
</p></abstract><kwd-group><kwd>DPP4，分子对接，2型糖尿病, DPP4</kwd><kwd> Molecular Dock</kwd><kwd> Type 2 Diabetes</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>靶向DPP4与2型糖尿病相关药物分子的对接研究<sup> </sup></title><p>李恒臻，庄立晖，刘哲，王晓艳<sup>*</sup></p><p>泰山医学院放射学院，山东 泰安</p><disp-formula id="hanspub.19994-formula11"><graphic xlink:href="http://html.hanspub.org/file/4-1570304x5_hanspub.png"  xlink:type="simple"/></disp-formula><p>收稿日期：2017年3月8日；录用日期：2017年3月24日；发布日期：2017年3月28日</p><disp-formula id="hanspub.19994-formula12"><graphic xlink:href="http://html.hanspub.org/file/4-1570304x6_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>DPP-4抑制剂作为一种治疗2型糖尿病的新型药物正在崭露头角，本文利用分子对接技术研究DPP4蛋白与5种抑制剂之间的对接研究，以期对新的抑制剂的研究提供帮助。结果表明：阿格列汀抑制剂与DPP4对接过程中与GLU206，TYR662，ARG125处结合形成氢键，与GLU205处形成盐桥；沙格列汀与DPP4对接过程中在GLU205，GLU206、TYR662，ARG125部位形成氢键，并在骨架的GLU205处形成氢键；利拉利汀与DPP4对接过程中在GLU205，TYR662，ARG125部位形成氢键，在GLU206处形成盐桥，而在TUR547处形成了π-π作用；西他列汀与DPP4对接过程中在GLU205，TYR662部位形成氢键，在GLU206处形成盐桥，而在TYR666处形成了π-π作用；维格列汀与DPP4对接过程中在GLU205部位形成氢键，在GLU206处形成盐桥。</p><p>关键词 :DPP4，分子对接，2型糖尿病</p><disp-formula id="hanspub.19994-formula13"><graphic xlink:href="http://html.hanspub.org/file/4-1570304x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2017 by authors and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="http://image.hanspub.org:8080\Html/htmlimages\1-2890033x\e70a10f1-7c93-45ea-9603-062237856e4b.png" /><img src="http://image.hanspub.org:8080\Html\htmlimages\1-2890033x\e898c85e-ffc4-45c9-b817-14224a4d6960.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>糖尿病是多病因导致的胰岛功能减退，胰岛素相对或绝对分泌不足所引起的、以血糖升高为特征的代谢紊乱综合征。其特点主要为持续的血糖升高，是继肿瘤、心血管疾病之后，又一严重威胁人类健康的重大疾病。据WHO最新公布的权威数据显示，全球糖尿病患者的人数已超过1.77亿，预计到2025年将达到3.7亿。2型糖尿病是全球性问题，占糖尿病总数的85%~90%，中国2型糖尿病患病人数已达5000万。2型糖尿病发病机制为胰岛素抵抗和胰岛β细胞功能逐渐下降 [<xref ref-type="bibr" rid="hanspub.19994-ref1">1</xref>] 。大量研究表明胰升糖素肽-1 (Glucagon-LikePeptide1, GLP-1)可通过多个途径参与机体血糖稳定调节，改善胰岛功能，延缓甚至逆转2型糖尿病病程的进展。有研究甚至显示GLP-1的作用缺陷从而引起β细胞功能障碍可能是导致个体发展为2型糖尿病的重要原因 [<xref ref-type="bibr" rid="hanspub.19994-ref2">2</xref>] ，但GLP-1在体内会被二肽基肽酶(dipeptidyl peptidase 4, DPP4)降解而失去活性(其半衰期大约为1分钟)。DPP4抑制剂可选择性的抑制DPP4的酶活性，阻止GLP-1裂解失活，提高活性GLP-1的血浆水平，增强其生理作用。DPP4抑制剂作为新一类口服降糖药物在2型糖尿病治疗中对血糖控制的有效性、良好的安全性和耐受性已经在大量的临床试验和实际应用中得到证实。</p><p>DPP4抑制剂有很多，为了进一步说明DPP4抑制剂是怎样与DPP4相互作用从而达到抑制的目的，本文利用分子对接技术将西他列汀(sitgliptin)、沙格列汀(saxagliptin)、利拉利汀(linagliptin)、阿格列汀(alogliptin)、维格列汀(vildagliptin)等小分子药物与DPP4的对接为例进行说明(分子结构如图1所示)。</p></sec><sec id="s4"><title>2. 材料与方法</title><p>药物小分子利用chemdraw进行优化，随后用maestro elements 2.2软件进行对接准备，受体DPP4准备及对接用的是Maestro10.2软件，操作界面用的win-64界面。</p><p>配体分子是通过美国加州大学药物化学系的Shoichet研究小组建立并维护的ZINC数据库下载mol2文件得到。利用maestro elements 2.2软件对配体分子通过加氢、PKa计算、能量最小化等进行预处理，最后导出结构为.mol2文件。</p><p>为了进行分子对接研究，蛋白质DPP4结构是从布鲁克港蛋白质数据库(http://www.rcsb.org/pdb/, Brookhaven protein data bank) [<xref ref-type="bibr" rid="hanspub.19994-ref4">4</xref>] 取得的，DPP4结构的PDB ID是2QOE，在分子对接中A链、B链结构对称，所以我们仅用A链来进行对接研究。对DPP4中的受体Q488移除，对蛋白质结构晶体利用</p><p>图1. 进行对接研究的配体分子结构</p><p>Maestro10.2软件进行同源建模优化晶体结构。利用Maestro10.2软件的glide-docking功能建立受体对接模型，随后将配体分子与受体进行对接。</p><p>DPP4与抑制剂之间的结合自由能是基于如下方程计算的，即体系的结合自由能为内能，溶剂效应(极性部分和非极性部分)，以及熵的贡献三者之和 [<xref ref-type="bibr" rid="hanspub.19994-ref5">5</xref>] [<xref ref-type="bibr" rid="hanspub.19994-ref6">6</xref>] ，本工作利用maestro中的MMGBSA方法来完成。</p><disp-formula id="hanspub.19994-formula14"><graphic xlink:href="http://html.hanspub.org/file/4-1570304x15_hanspub.png"  xlink:type="simple"/></disp-formula><p>相互作用能如表2所示。</p></sec><sec id="s5"><title>3. 结果与讨论</title><p>表1给出了配体与受体的对接情况，分子对接的实验值及理论值的比较 [<xref ref-type="bibr" rid="hanspub.19994-ref3">3</xref>] 。表2给出了用MM-GBSA</p><p>图2. 分子对接后的二维平面图</p><p>方法计算的结合能，配体与受体的相互作用位点、作用距离等。图2给出了DPP4与配体对接的二维结构图。从图上可以看出配体阿格列汀与DPP4对接过程中与GLU206，TYR662，ARG125结合形成氢键，与GLU205形成盐桥；沙格列汀与DPP4对接过程中在GLU205，GLU206、TYR662，ARG125部位形成氢键，并在骨架的GLU205处形成氢键；利拉利汀与DPP4对接过程中在GLU205，TYR662，ARG125部位形成氢键，在GLU206处形成盐桥，而在TUR547处形成了 作用；西他列汀与DPP4对接过程中在GLU205，TYR662部位形成氢键，在GLU206处形成盐桥，而在TYR666处形成了 作用；维格列汀与DPP4对接过程中在GLU205部位形成氢键，在GLU206处形成盐桥，具体结合情况如表2所示。</p></sec><sec id="s6"><title>4. 展望</title><p>DPP4抑制剂同时作用于胰岛α和β细胞，调节胰岛细胞功能，在强效降糖的同时，减少低血糖的发</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> The docking residue of DPP4 with 5 molecule</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >alogliptin</th><th align="center" valign="middle" >alogliptin [<xref ref-type="bibr" rid="hanspub.19994-ref3">3</xref>]</th><th align="center" valign="middle" >linagliptin</th><th align="center" valign="middle" >linagliptin [<xref ref-type="bibr" rid="hanspub.19994-ref3">3</xref>]</th><th align="center" valign="middle" >saxagliptin</th><th align="center" valign="middle" >Saxagliptin [<xref ref-type="bibr" rid="hanspub.19994-ref3">3</xref>]</th><th align="center" valign="middle" >sitagliptin</th><th align="center" valign="middle" >Sitagliptin [<xref ref-type="bibr" rid="hanspub.19994-ref3">3</xref>]</th><th align="center" valign="middle" >vildagliptin</th><th align="center" valign="middle" >Vildagliptin [<xref ref-type="bibr" rid="hanspub.19994-ref3">3</xref>]</th></tr></thead><tr><td align="center" valign="middle" >对接值</td><td align="center" valign="middle" >−5.793</td><td align="center" valign="middle" >−7.92</td><td align="center" valign="middle" >−6.155</td><td align="center" valign="middle" >−7.91</td><td align="center" valign="middle" >−7.498</td><td align="center" valign="middle" >−7.61</td><td align="center" valign="middle" >−7.895</td><td align="center" valign="middle" >−7.1</td><td align="center" valign="middle" >−6.176</td><td align="center" valign="middle" >−7.43</td></tr><tr><td align="center" valign="middle" >实验pki值 [<xref ref-type="bibr" rid="hanspub.19994-ref4">4</xref>]</td><td align="center" valign="middle" >−8.5</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >−9</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >−9.2</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >−8.1</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >−7.8</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  rowspan="23"  >与受体 相互作 用的残 基(<sup>*</sup>为形 成氢键、 盐桥及 Pi-stacking 的部位)</td><td align="center" valign="middle" >HIS126</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >HIS126</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >HIS126</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >HIS126</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >TRP201</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >ASN710</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >ASN710</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >ASN710</td><td align="center" valign="middle" >ASN710<sup>*</sup></td><td align="center" valign="middle" >ASN710</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >ASN710</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >GLU205<sup>*</sup></td><td align="center" valign="middle" >GLU205<sup>*</sup></td><td align="center" valign="middle" >GLU205<sup>*</sup></td><td align="center" valign="middle" >GLU205<sup>*</sup></td><td align="center" valign="middle" >GLU205<sup>*</sup></td><td align="center" valign="middle" >GLU205<sup>*</sup></td><td align="center" valign="middle" >GLU205<sup>*</sup></td><td align="center" valign="middle" >GLU205<sup>*</sup></td><td align="center" valign="middle" >GLU205<sup>*</sup></td><td align="center" valign="middle" >GLU205<sup>*</sup></td></tr><tr><td align="center" valign="middle" >GLU206<sup>*</sup></td><td align="center" valign="middle" >GLU206<sup>*</sup></td><td align="center" valign="middle" >GLU206<sup>*</sup></td><td align="center" valign="middle" >GLU206<sup>*</sup></td><td align="center" valign="middle" >GLU206<sup>*</sup></td><td align="center" valign="middle" >GLU206<sup>*</sup></td><td align="center" valign="middle" >GLU206<sup>*</sup></td><td align="center" valign="middle" >GLU206<sup>*</sup></td><td align="center" valign="middle" >GLU206<sup>*</sup></td><td align="center" valign="middle" >GLU206<sup>*</sup></td></tr><tr><td align="center" valign="middle" >TYR662<sup>*</sup></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >TYR662<sup>*</sup></td><td align="center" valign="middle" >TYR662<sup>*</sup></td><td align="center" valign="middle" >TYR662<sup>*</sup></td><td align="center" valign="middle" >TYR662<sup>*</sup></td><td align="center" valign="middle" >TYR662<sup>*</sup></td><td align="center" valign="middle" >TYR662<sup>*</sup></td><td align="center" valign="middle" >TYR662</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >ASP663</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >ASP663</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >ASP663</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >ASP663</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >TYR666</td><td align="center" valign="middle" >TYR666<sup>*</sup></td><td align="center" valign="middle" >TYR666</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >TYR666</td><td align="center" valign="middle" >TYR666<sup>*</sup></td><td align="center" valign="middle" >TYR666<sup>*</sup></td><td align="center" valign="middle" >TYR666<sup>*</sup></td><td align="center" valign="middle" >TYR666</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >SER630</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >SER630</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >SER630</td><td align="center" valign="middle" >SER630<sup>*</sup></td><td align="center" valign="middle" >SER630</td><td align="center" valign="middle" >SER630<sup>*</sup></td><td align="center" valign="middle" >SER630</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >HIS740</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >HIS740</td><td align="center" valign="middle" >HIS740<sup>*</sup></td><td align="center" valign="middle" >HIS740</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >HIS740</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >ARG125<sup>*</sup></td><td align="center" valign="middle" >ARG125<sup>*</sup></td><td align="center" valign="middle" >ARG125</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >ARG125<sup>*</sup></td><td align="center" valign="middle" >ARG125<sup>*</sup></td><td align="center" valign="middle" >ARG125</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >ARG125</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >TRP629</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >TRP629</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >TYR547</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >TRP629</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >TYR547</td><td align="center" valign="middle" >TYR547<sup>*</sup></td><td align="center" valign="middle" >TYR547<sup>*</sup></td><td align="center" valign="middle" >TYR547<sup>*</sup></td><td align="center" valign="middle" >PHE357</td><td align="center" valign="middle" >TYR547<sup>*</sup></td><td align="center" valign="middle" >TYR547</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >TYR547</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >CYS551</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >SER552</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >SER209</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >PHE357</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >GLY549</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >PHE357</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >ARG669</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >SER209</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >PRO550</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >GLN553</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >VAL711</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >ARG669</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >SER552</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >SER209</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >VAL656</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >VAL711</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >PHE357<sup>*</sup></td><td align="center" valign="middle" >PHE357<sup>*</sup></td><td align="center" valign="middle" >GLY628</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >TYR631</td><td align="center" valign="middle" >PHE357<sup>*</sup></td><td align="center" valign="middle" >VAL656</td><td align="center" valign="middle" >PHE357<sup>*</sup></td><td align="center" valign="middle" >PHE357</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >GLN553</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >ASP545</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >VAL207</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >TYR631</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >SER209</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >TRP627</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >VAL207</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >VAL711</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >LYS554</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >TRP201</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >VAL656</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >ARG669</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >TRP659</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >TYR631</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >ARG358</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >TRP659</td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>表1. 与五种小分子对接的DPP4的残基</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> The interacting distance during docking between DPP4 and 5 molecule</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >配体名称</th><th align="center" valign="middle" ></th><th align="center" valign="middle"  colspan="7"  >相互作用距离及类型</th></tr></thead><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >相互作用能</td><td align="center" valign="middle" >GLU205</td><td align="center" valign="middle" >GLU206</td><td align="center" valign="middle" >TYR662</td><td align="center" valign="middle" >ARG125</td><td align="center" valign="middle" >PHE357</td><td align="center" valign="middle" >TYR547</td><td align="center" valign="middle" >TYR666</td></tr><tr><td align="center" valign="middle" >alogliptin</td><td align="center" valign="middle" >−47.9805</td><td align="center" valign="middle" >salt bridge 3.39505</td><td align="center" valign="middle" >2.039 (H-bond)</td><td align="center" valign="middle" >2.35119 (H-bond)</td><td align="center" valign="middle" >2.52806 (H-bond)</td><td align="center" valign="middle" >Pi-stacking 4.51539</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >linagliptin</td><td align="center" valign="middle" >−64.5003</td><td align="center" valign="middle" >2.33181 (H-bond)</td><td align="center" valign="middle" >salt bridge 2.9098</td><td align="center" valign="middle" >2.53557 (H-bond)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >salt bridge 5.28194</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >saxagliptin</td><td align="center" valign="middle" >−67.8099</td><td align="center" valign="middle" >2.40782 (H-bond) (side chain) 2.23433 (H-bond) (backbone)</td><td align="center" valign="middle" >1.71423 (H-bond)</td><td align="center" valign="middle" >2.5392 (H-bond)</td><td align="center" valign="middle" >2.22074 (H-bond)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >sitagliptin</td><td align="center" valign="middle" >−79.1987</td><td align="center" valign="middle" >1.89363 (H-bond)</td><td align="center" valign="middle" >salt bridge 2.77566</td><td align="center" valign="middle" >1.77592 (H-bond)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >Pi-stacking 4.65316</td></tr><tr><td align="center" valign="middle" >vildagliptin</td><td align="center" valign="middle" >−46.9239</td><td align="center" valign="middle" >1.73979 (H-bond)</td><td align="center" valign="middle" >salt bridge 4.87331</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>表2. DPP4与五种分子对接过程中的相互作用距离</p><p>生，还可以保护胰岛细胞，延缓糖尿病的进展，在T2DM管理中扮演重要角色。与西方人群不同的是，中国血糖代谢异常人群β细胞功能障碍可能更为突显。因此，在病程早期纳入保护β细胞功能的药物进行联合治疗，可能更容易获得持久的血糖控制。本文通过DPP4与5种临床抑制剂的对接研究以期为新的抑制剂的研究提供帮助。</p></sec><sec id="s7"><title>基金项目</title><p>国家级大学生创新创业项目(No.201510439136，No.201610439071，No.201610439080)。</p></sec><sec id="s8"><title>文章引用</title><p>李恒臻,庄立晖,刘 哲,王晓艳. 靶向DPP4与2型糖尿病相关药物分子的对接研究 The Docking of Protein DPP4 and Drug Molecules for Type 2 Diabetes[J]. 临床医学进展, 2017, 07(01): 16-22. http://dx.doi.org/10.12677/ACM.2017.71004</p></sec><sec id="s9"><title>参考文献 (References)</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.19994-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Bonner, W.S. (2000) Life and Death of the Pancreatic Beta Cells. Trends in Endocrinology and Metabolism, 11, 375-378.</mixed-citation></ref><ref id="hanspub.19994-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Lugari, R., Dei Cas, A., Ugolotti, D., et al. (2002) Evidence for Early Impairment of Glucagon-Like Peptide1-Induced insulin Secretion in Human Type 2 (Non Insulin-Dependent) Diabetes. Hormone and Metabolic Research, 34, 150-154.  
&lt;br&gt;https://doi.org/10.1055/s-2002-23199</mixed-citation></ref><ref id="hanspub.19994-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Anitha, K., Gopi, G. and Kumar, P.S. (2013) Molecular Docking Study on Dipeotidyl Peptidase-4 Inhibitors. International Journal of Research and Development in Pharmacy and Life Sciences, 2, 602-610.</mixed-citation></ref><ref id="hanspub.19994-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">http://www.rcsb.org/pdb/.</mixed-citation></ref><ref id="hanspub.19994-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Wang, J.M., Hou, T.J. and Xu, X.J. (2006) Recent Advances in Free Energy Calcula-tions with a Combination of Molecular Mechanics and Continuum Models. Current Computer-Aided Drug Design, 2, 287-306.  
&lt;br&gt;https://doi.org/10.2174/157340906778226454</mixed-citation></ref><ref id="hanspub.19994-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Kollman, P.A., Massova, I., Reyes, C., et al. (2000) Calculating Structures and Free Energies of Complex Molecules: Combining Molecular Mechanics and Continuum Models. Accounts of Chemical Research, 33, 889-897.  
&lt;br&gt;https://doi.org/10.1021/ar000033j</mixed-citation></ref></ref-list></back></article>